Marketing Products Without Getting Hammered by FDA - 2-day In-person Seminar
March 5 - 6, 2015 - Baltimore, MD CA USGlobalCompliancepanel
support@globalcompliancepanel.com
Phone:8004479407
Fax: 302-288-6884
Overview: With this seminar you will learn how to navigate FDA's legal requirements and its interpretations for enforcement purposes. The agency now applies the principles of cognitive psychology to aid in its determination of what a message really conveys. This becomes a new factor in trying to stay within FDA's legal corral. This conference will provide insight on how to manage your marketing activity and gauge what regulatory risks your business is willing to accept. You will learn how corporate management requires cooperation between marketing, regulatory affairs, legal counsel, manufacturing, engineering and finance departments. You will understand that a weak link in any department leaves the entire corporation vulnerable to FDA enforcement. Most importantly, you will understand the boundaries that FDA uses and how easy it is to cross them. With information from this course, you can step back and rationally evaluate your firm's regulatory profile for advertising and promotion. Why should you attend: If you go "off label" with advertising and promotion, you become embroiled in FDA's advertising and promotion requirements. For devices, the law is weak and lacks legal clarity. For drugs, FDA's law and regulations are extensive and have violated Constitutional protections. Depending on your point of FDA's promotion and advertising requirements can help you or hurt you? There is an inherent conflict in interests. In any case, you need to identify practical criteria to make marketing decisions. That begs the question of whether or not marketing managers and regulatory affairs managers will even try to agree on an issue. FDA's Center for Devices and Radiological Health (CDRH) has never issued a comprehensive guidance on advertising and promotion. You are on your own. CDER has established a pervasive and expanding program. For example, policing social media has become a new regulatory responsibility. Bottom line, do you know when you are running afoul of FDA's requirements or are you guessing? It's become a brooding nightmare for you and consumers. Areas Covered in the Session: FDA's legal authority and Constitutional limitations FDA requirements and exemptions FDA guidance documents, such as for social media, direct-to-onsumer advertising, message formatting and providing risk/benefit information Warning Letters Who will benefit: Managers for: Regulatory Affairs Quality Assurance Manufacturing FDA consultants and legal counsel Agenda: Day One Lecture 1: FDA legal authority FTC / mass media DOJ / False Claims FDA application of the FD&C statute and regulations False and Misleading Lecture 2: Cognitive psychology Lecture 3: Promotion and Advertising: scope of labeling Definitions for "label" and "labeling" Hard copy and electronic Testimonials Blogs Sales force What is "off-label"? Practice of Medicine exemption Drugs authority Devices Dietary supplements Lecture 4: Supreme Court / commercial free speech Constitutional protection Safe harbor Lecture 5: Policy FDA organizational responsibility FDA Guidance Balanced disclosure of risk vs. benefit Social Media Direct to Consumer Advertising Day Two: Lecture 6: Hypothetical Workshop Direct to consumer advertising Federal Trade Commission authority Fair and balanced information Context and format Script versus message Target population Aspirations Emotional factors False and misleading information Statutory basis (21 U.S.C. 352(a)) New use Comparative claims Claims for safety and effectiveness Sales for solicitation Off label use (Group Hypothetical) Lecture 7: FDA Warning Letters Lecture 8: Corporate management responsibility FDA - false and misleading FTC - false advertising DOJ - false clai Speaker: Casper Uldriks through his firm "Encore Insight LLC," brings over 32 years of experience from the FDA. As an investigator, he was responsible for countless 483s, scores of Warning Letters, injunctions, individual seizures, mass seizures and was coined by industry as FDA's "Darth Vader. Price: $1,295.00 Quick Contact: GlobalCompliancePanel USA Phone:800-447-9407 Fax: 302-288-6884 support@globalcompliancepanel.com http://www.globalcompliancepanel.com